Should Zelen pre-randomised consent designs be used in some neonatal trials?

My aim is to suggest that there is a case for using a randomised consent design in some neonatal trials. As an example I use the trials of extracorporeal membrane oxygenation (ECMO) in neonates suffering pulmonary hypertension. In some trials the process of obtaining consent has the potential to har...

Full description

Saved in:  
Bibliographic Details
Main Author: Allmark, P. (Author)
Format: Electronic Article
Language:English
Check availability: HBZ Gateway
Journals Online & Print:
Drawer...
Fernleihe:Fernleihe für die Fachinformationsdienste
Published: BMJ Publ. 1999
In: Journal of medical ethics
Year: 1999, Volume: 25, Issue: 4, Pages: 325-329
Online Access: Volltext (JSTOR)
Volltext (kostenfrei)
Volltext (kostenfrei)

MARC

LEADER 00000caa a22000002 4500
001 1816118532
003 DE-627
005 20230427025701.0
007 cr uuu---uuuuu
008 220908s1999 xx |||||o 00| ||eng c
024 7 |a 10.1136/jme.25.4.325  |2 doi 
035 |a (DE-627)1816118532 
035 |a (DE-599)KXP1816118532 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 1  |2 ssgn 
100 1 |a Allmark, P.  |e VerfasserIn  |4 aut 
245 1 0 |a Should Zelen pre-randomised consent designs be used in some neonatal trials? 
264 1 |c 1999 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
520 |a My aim is to suggest that there is a case for using a randomised consent design in some neonatal trials. As an example I use the trials of extracorporeal membrane oxygenation (ECMO) in neonates suffering pulmonary hypertension. In some trials the process of obtaining consent has the potential to harm the subject, for example, by disappointing those who end in the control group and by creating additional anxiety at times of acute illness. An example of such were the trials of extracorporeal membrane oxygenation (ECMO) in neonates suffering pulmonary hypertension. Pre-randomised consent could avoid or lessen these harms. However, a number of ethical objections are made to these research designs. They involve denial of information, using people, denial of choice, and "overselling" of allocated treatment. Furthermore, they are the wrong response; better communication might be the answer, for example. I argue that these objections are not completely persuasive. However, they are enough to suggest caution in the use of such designs. 
773 0 8 |i Enthalten in  |t Journal of medical ethics  |d London : BMJ Publ., 1975  |g 25(1999), 4, Seite 325-329  |h Online-Ressource  |w (DE-627)323607802  |w (DE-600)2026397-1  |w (DE-576)260773972  |x 1473-4257  |7 nnns 
773 1 8 |g volume:25  |g year:1999  |g number:4  |g pages:325-329 
856 |3 Volltext  |u http://www.jstor.org/stable/27718330  |x JSTOR 
856 |u https://jme.bmj.com/content/medethics/25/4/325.full.pdf  |x unpaywall  |z Vermutlich kostenfreier Zugang  |h publisher [open (via free pdf)] 
856 4 0 |u https://doi.org/10.1136/jme.25.4.325  |x Resolving-System  |z kostenfrei  |3 Volltext 
856 4 0 |u http://jme.bmj.com/content/25/4/325.abstract  |x Verlag  |z kostenfrei  |3 Volltext 
935 |a mteo 
936 u w |d 25  |j 1999  |e 4  |h 325-329 
951 |a AR 
ELC |a 1 
ITA |a 1  |t 1 
LOK |0 000 xxxxxcx a22 zn 4500 
LOK |0 001 4185570422 
LOK |0 003 DE-627 
LOK |0 004 1816118532 
LOK |0 005 20220908053301 
LOK |0 008 220908||||||||||||||||ger||||||| 
LOK |0 035   |a (DE-Tue135)IxTheo#2022-08-02#5EF01877A1BDC1B1A365B840EA12586294D42C23 
LOK |0 040   |a DE-Tue135  |c DE-627  |d DE-Tue135 
LOK |0 092   |o n 
LOK |0 852   |a DE-Tue135 
LOK |0 852 1  |9 00 
LOK |0 866   |x JSTOR#http://www.jstor.org/stable/27718330 
LOK |0 935   |a ixzs  |a ixrk  |a zota 
OAS |a 1 
ORI |a SA-MARC-ixtheoa001.raw